TYLER ULMER

Allopathic & Osteopathic Physicians|Family Medicine KERRVILLE, TX NPI 1801419627

General Payments — all program years on this page

$553.34

  • Category: General Payments
  • Program years: PY2023–2024
  • Record count: 29
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $402.03 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $402.0321

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2023 $151.318
2024 $402.0321

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087427652 Novartis Pharmaceuticals Corporation $19.20 01/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087427654 Novartis Pharmaceuticals Corporation $19.24 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105413842 AstraZeneca Pharmaceuticals LP $19.49 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105705946 AstraZeneca Pharmaceuticals LP $13.33 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105832995 AstraZeneca Pharmaceuticals LP $17.00 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106258954 ABBVIE INC. $18.42 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106258956 ABBVIE INC. $14.11 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114937433 Exact Sciences Corporation $14.44 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114937436 Exact Sciences Corporation $13.78 11/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115906102 GlaxoSmithKline, LLC. $14.19 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116430987 GlaxoSmithKline, LLC. $13.81 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116435253 GlaxoSmithKline, LLC. $13.92 08/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116540143 GlaxoSmithKline, LLC. $13.20 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116620859 GlaxoSmithKline, LLC. $19.57 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135439566 Lilly USA, LLC $15.66 07/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135469033 Lilly USA, LLC $14.52 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137690585 Takeda Pharmaceuticals U.S.A., Inc. $15.27 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147996102 ACADIA Pharmaceuticals Inc $34.79 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147996104 ACADIA Pharmaceuticals Inc $32.47 06/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147996106 ACADIA Pharmaceuticals Inc $32.48 09/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147996108 ACADIA Pharmaceuticals Inc $33.14 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.